Sensei Biotherapeutics (SNSE)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Sensei Biotherapeutics (SNSE) trades at $13.85 with AI Score 49/100 (Grade C). Sensei Biotherapeutics, Inc. is a biopharmaceutical company focused on developing immunotherapies for cancer. Market cap: $18.59M, Sector: Healthcare.
Price live · AI analysis from May 4, 2026Analyst Coverage for SNSE: SNSE does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates SNSE against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
SNSE: the 1 perspectives are evenly split.
How is this calculated? →Sensei Biotherapeutics (SNSE) Healthcare & Pipeline Overview
Sensei Biotherapeutics, Inc. is a biopharmaceutical company specializing in the discovery and development of cancer immunotherapies. Their ImmunoPhage and Tumor Microenvironment Activated Biologics platforms represent a novel approach to cancer treatment by leveraging the body's immune system. The company's pipeline includes monoclonal antibodies and vaccines targeting various tumor antigens.
What Is the Investment Thesis for SNSE?
Sensei Biotherapeutics presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's ImmunoPhage and Tumor Microenvironment Activated Biologics platforms offer a novel approach to cancer immunotherapy, potentially addressing unmet needs in various cancer types. A key value driver is the advancement of its pipeline, particularly SNS-101 and SNS-401-NG, through clinical trials. Upcoming data readouts from these trials will be critical catalysts. The company's collaboration with The University of Washington also adds potential value. However, the company's small market capitalization of $18.59M and limited resources pose significant risks. Successful clinical development and regulatory approval are crucial for realizing the company's potential.
Based on FMP financials and quantitative analysis
SNSE Key Highlights
- Market capitalization of $18.59M reflects the company's early stage and potential for growth.
- Profit margin of 434.7% suggests potential profitability if key pipeline products are commercialized.
- Beta of -0.10 indicates low correlation with the overall market, potentially offering diversification benefits.
- Focus on novel immunotherapy platforms differentiates Sensei Biotherapeutics from competitors.
- Collaboration with The University of Washington provides access to research and development expertise.
Who Are SNSE's Competitors?
SNSE is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| ABVX Abivax S.A. | $145.38 | +0.51% | $9.53B | 76 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
| GLUE Monte Rosa Therapeutics, Inc. | $23.06 | -4.75% | $1.50B | 68 |
| RNAM Avidity Biosciences Inc | $72.86 | +0.05% | $11.26B | 68 |
| DAWN Day One Biopharmaceuticals, Inc. | $21.53 | +0.00% | $2.22B | 68 |
| TLX Telix Pharmaceuticals Limited | $12.15 | +2.36% | $4.12B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are SNSE's Key Strengths?
- Innovative ImmunoPhage platform.
- Focus on cancer immunotherapy.
- Collaboration with The University of Washington.
What Are SNSE's Weaknesses?
- Limited financial resources.
- Small number of employees.
- Early-stage pipeline.
What Could Drive SNSE Stock Higher?
- Clinical trial data readouts for SNS-101.
- Clinical trial data readouts for SNS-401-NG.
- Progress in collaboration with The University of Washington.
- Expansion of the ImmunoPhage platform to new cancer targets.
What Are the Key Risks for SNSE?
- Financial-distress signal — its Altman Z-Score of -4.18 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures for SNS-101 or SNS-401-NG.
- Regulatory delays or rejection of Sensei's product candidates.
- Competition from larger pharmaceutical companies with more resources.
- Dependence on securing additional funding to support operations.
What Are the Growth Opportunities for SNSE?
- Advancement of SNS-101: SNS-101, a monoclonal antibody for the treatment of cancer, represents a significant growth opportunity for Sensei Biotherapeutics. Successful completion of clinical trials and subsequent regulatory approval could lead to substantial revenue generation. The market for monoclonal antibody therapies in oncology is substantial, with projections reaching billions of dollars annually. The timeline for potential commercialization depends on clinical trial outcomes, but could be within the next 3-5 years.
- Development of SNS-401-NG: SNS-401-NG, an ImmunoPhage vaccine targeting multiple tumor antigens, offers another avenue for growth. This vaccine has the potential to address a broad range of cancers. The market for cancer vaccines is expanding, driven by the increasing understanding of tumor-associated antigens and the development of more effective vaccine technologies. Clinical trials are underway, and positive results could accelerate its path to market.
- Expansion of ImmunoPhage Platform: The ImmunoPhage platform has the potential to be applied to a variety of different cancers. Expanding the platform to target new tumor antigens and develop new ImmunoPhage vaccines would increase the company's pipeline and create additional growth opportunities. This platform's versatility could provide a competitive advantage.
- Leveraging Tumor Microenvironment Activated Biologics: Sensei Biotherapeutics' Tumor Microenvironment Activated Biologics platform offers a unique approach to cancer immunotherapy. Further development and application of this platform could lead to the discovery of novel therapeutics that selectively target the tumor microenvironment. This targeted approach has the potential to improve treatment efficacy and reduce side effects.
- Partnerships and Collaborations: Strategic partnerships and collaborations with larger pharmaceutical companies or research institutions could provide Sensei Biotherapeutics with access to additional funding, expertise, and resources. These collaborations could accelerate the development and commercialization of its pipeline products. The company's existing collaboration with The University of Washington demonstrates its ability to forge such partnerships.
What Opportunities Does SNSE Have?
- Advancement of clinical trials.
- Expansion of ImmunoPhage platform.
- Strategic partnerships and collaborations.
What Threats Does SNSE Face?
- Clinical trial failures.
- Regulatory hurdles.
- Competition from larger pharmaceutical companies.
What Are SNSE's Competitive Advantages?
- Proprietary ImmunoPhage platform technology.
- Expertise in tumor microenvironment biology.
- Intellectual property protection for its pipeline products.
What Does SNSE Do?
Sensei Biotherapeutics, Inc., founded in 1999 and headquartered in Rockville, Maryland, is a biopharmaceutical company dedicated to discovering and developing innovative immunotherapies for cancer. Formerly known as Panacea Pharmaceuticals, Inc., the company has evolved to focus on leveraging the body's immune system to combat tumors. Sensei's core technology revolves around two proprietary platforms: ImmunoPhage and Tumor Microenvironment Activated Biologics. The ImmunoPhage platform utilizes bacteriophages to stimulate a focused and coordinated immune response, while the Tumor Microenvironment Activated Biologics platform aims to unlock the anti-tumor potential of T-cells. Sensei is developing SNS-101, a monoclonal antibody for cancer treatment, and SNS-401-NG, an ImmunoPhage vaccine targeting multiple tumor antigens. Additionally, Sensei Biotherapeutics collaborates with The University of Washington to research and develop a Merkel cell carcinoma vaccine. With a small team of 14 employees, Sensei Biotherapeutics is focused on advancing its pipeline of novel immunotherapies.
What Products and Services Does SNSE Offer?
- Develop immunotherapies for cancer treatment.
- Utilize the ImmunoPhage platform to induce immune responses.
- Employ Tumor Microenvironment Activated Biologics to activate T-cells.
- Develop monoclonal antibodies for cancer therapy.
- Create vaccines targeting tumor antigens.
- Collaborate with research institutions to advance cancer research.
How Does SNSE Make Money?
- Develop and out-license or sell immunotherapeutic products.
- Generate revenue through research and development collaborations.
- Potentially receive milestone payments and royalties upon successful product development and commercialization.
What Industry Does SNSE Operate In?
Sensei Biotherapeutics operates within the rapidly evolving biotechnology industry, specifically in the cancer immunotherapy market. This market is characterized by intense competition and significant unmet needs. The global cancer immunotherapy market is projected to reach billions of dollars in the coming years, driven by advances in understanding the immune system's role in cancer and the development of novel therapeutic approaches. Sensei's ImmunoPhage and Tumor Microenvironment Activated Biologics platforms position it to potentially capture a share of this growing market. Competition includes established pharmaceutical companies and other emerging biotechnology firms.
Who Are SNSE's Key Customers?
- Future cancer patients who may benefit from Sensei's immunotherapies.
- Pharmaceutical companies interested in licensing or acquiring Sensei's technologies.
- Research institutions collaborating with Sensei on cancer research.
F-Score 3/9Financial Health
Sensei Biotherapeutics's Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -4.18 places it in the distress zone, a signal of elevated financial risk.
Key Financial Metrics
Return on assets is -89.8%, showing how much profit it generates from its asset base. Its free cash flow yield is -77.7%, a gauge of the cash the business throws off relative to its market value. A current ratio of 14.39 indicates the company holds enough short-term assets to cover its near-term obligations.
Sensei Biotherapeutics (SNSE) Valuation Context
Valued at $18.59M, SNSE is classified as a micro-cap stock. Relative to its peer group, SNSE's quantitative score of 49/100 is below the peer average of 76/100.
FY2026 estForward Outlook
Wall Street analysts project Sensei Biotherapeutics revenue of about $0 for fiscal 2026, with EPS near $-101.67.
SNSE Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying indicates confidence in the company's future prospects, suggesting that key stakeholders believe in its potential.
- Community sentiment has shifted positively as discussions around innovative therapies gain traction, boosting investor interest.
- Recent partnerships with research institutions have enhanced credibility, positioning the company as a serious player in biotherapeutics.
- Increased media coverage highlighting advancements in their pipeline is generating buzz and attracting more attention from retail investors.
Bear Case
- Market skepticism persists regarding the commercialization timeline of their products, leading to doubts about short-term viability.
- Social sentiment shows some frustration among investors over delays in clinical trial results, which could impact credibility.
- Increased competition in the biotherapeutics space raises concerns about market share and differentiation from peers.
- Recent regulatory challenges faced by similar companies have heightened caution among investors, leading to bearish sentiment in the community.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
SNSE Latest News
-
This MarketAxess Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Thursday
benzinga · Jun 11, 2026
-
This Henry Schein Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
benzinga · Jun 11, 2026
-
This Daktronics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
benzinga · Jun 11, 2026
-
12 Health Care Stocks Moving In Monday's Pre-Market Session
benzinga · Jun 8, 2026
SNSE Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for SNSE.
Price Targets
Wall Street price target analysis for SNSE.
SNSE MoonshotScore
What does this score mean?
The MoonshotScore rates SNSE's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Latest News
This MarketAxess Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Thursday
This Henry Schein Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
This Daktronics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
12 Health Care Stocks Moving In Monday's Pre-Market Session
Leadership: Christopher W. Gerry
CEO
Christopher W. Gerry serves as the Chief Executive Officer of Sensei Biotherapeutics, Inc. His background includes extensive experience in the biopharmaceutical industry, with a focus on corporate strategy, business development, and financial management. He has held leadership positions at various biotechnology companies, contributing to the development and commercialization of innovative therapies. His expertise encompasses drug development, regulatory affairs, and commercial operations. He is responsible for managing the company's overall strategic direction and operations, overseeing a team of 14 employees.
Track Record: Under Christopher W. Gerry's leadership, Sensei Biotherapeutics has focused on advancing its ImmunoPhage and Tumor Microenvironment Activated Biologics platforms. Key milestones include progressing SNS-101 and SNS-401-NG through preclinical and clinical development stages. He has also overseen the company's collaboration with The University of Washington to develop a Merkel cell carcinoma vaccine.
Sensei Biotherapeutics Healthcare Stock: Key Questions Answered
What does Sensei Biotherapeutics, Inc. do?
Sensei Biotherapeutics, Inc. is a biopharmaceutical company focused on the discovery and development of cancer immunotherapies. The company's core technology revolves around two proprietary platforms: ImmunoPhage and Tumor Microenvironment Activated Biologics. The ImmunoPhage platform utilizes bacteriophages to stimulate a focused and coordinated immune response, while the Tumor Microenvironment Activated Biologics platform aims to unlock the anti-tumor potential of T-cells. Sensei is developing SNS-101, a monoclonal antibody for cancer treatment, and SNS-401-NG, an ImmunoPhage vaccine targeting multiple tumor antigens.
What do analysts say about SNSE stock?
Given the company's small market capitalization and early-stage pipeline, analyst coverage of SNSE stock may be limited. Any available analyst reports would likely focus on the potential of Sensei's ImmunoPhage and Tumor Microenvironment Activated Biologics platforms, as well as the progress of its clinical trials. Key valuation metrics would likely include potential peak sales of its product candidates and the probability of success in clinical development. Investors should conduct their own due diligence and consider the risks associated with investing in a small-cap biotechnology company.
What are the main risks for SNSE?
Sensei Biotherapeutics faces several key risks, including the potential for clinical trial failures, regulatory hurdles, and competition from larger pharmaceutical companies with more resources. The company is also dependent on securing additional funding to support its operations. Clinical trial failures for SNS-101 or SNS-401-NG would significantly impact the company's prospects. Regulatory delays or rejection of Sensei's product candidates could also hinder its progress. Competition from larger companies with established immunotherapy products poses a significant challenge.
What are the key factors to evaluate for SNSE?
Sensei Biotherapeutics (SNSE) holds an AI score of 49/100 (low). Not financial advice.
How frequently does SNSE data refresh on this page?
SNSE prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven SNSE's recent stock price performance?
Sensei Biotherapeutics (SNSE) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative ImmunoPhage platform. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider SNSE overvalued or undervalued right now?
Valuing Sensei Biotherapeutics (SNSE) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying SNSE?
Before investing in Sensei Biotherapeutics (SNSE), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- Investment in biotechnology companies involves significant risks.